KCNQ3 and depressive disorder: Gene therapy directed to elicit overexpression of KCNQ3 in dopaminergic neurons of the ventral tegmental area and the administration of ezogabine (retigabine) locally and systemically normalized depression-like behaviors and neural hyperactivity [33].